Louisiana Clinical Trials Report — April 2026

For Louisiana residents considering participation in clinical trials, April 2026 presents a critical window to act, particularly for studies nearing their enrollment deadlines. Across the state, 55 clinical trials are scheduled to close within the next 90 days. This urgency extends to healthy volunteers, with 10 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, respiratory issues, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon in Louisiana include:

• Colon cancer
• Acute limb ischemia
• ARDS (moderate or severe)
• AHRF
• Anatomic stage II breast cancer AJCC V8
• Anatomic stage III breast cancer AJCC V8
• Advanced breast cancer
• Ascites hepatic
• Asthma
• Attention-deficit/hyperactivity disorder

New Horizons in Louisiana Research: Major Trials Launch

This month brings several high-profile new trials to Louisiana, including significant Phase 2 and 3 studies from major pharmaceutical companies and research organizations. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from oncology to infectious disease prevention.

• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial aims to enroll 588 participants to assess the efficacy and safety of this new approach.
• Westat is launching NCT07510048, "Combatting HIV Or Other STIs Early (CHOOSE) in an RCT of mHealth Tool Support." This Phase 2 study, designed for 200 participants, seeks to optimize and assess an integrated mHealth package for improving HIV PrEP uptake and adherence among young people.
• AstraZeneca is initiating NCT07525375, a Phase 2 study to investigate lung function with two different doses of inhaled glycopyrronium taken with BFF compared to BFF in participants 4 to less than 12 years of age with asthma. This trial involves 69 participants.
• Jazz Pharmaceuticals is sponsoring NCT07533942, "A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma." This Phase 2 study will recruit 30 participants with Grade 2 and 3 meningiomas who have failed prior therapy, evaluating the antitumor activity and safety of JZP3507.

Expanding Opportunities for Healthy Volunteers

For individuals in Louisiana without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 7 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 87 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and helping advance our understanding of health.

Beyond healthy volunteer options, the new trials this month also cater to specific demographics. 2 of the new studies include children, offering families a chance to participate. Additionally, 4 new trials are open to older adults, ensuring that senior populations have ample opportunity to contribute. One new trial is specifically designed for male participants.

Louisiana's Research Footprint: Where New Trials Are Opening

Louisiana's clinical research landscape continues to grow, with 7 new trials opening this month, matching the number of new trials launched in March 2026. Overall, the state boasts 855 clinical trials currently recruiting across 46 cities and 642 research sites, demonstrating a robust and widespread commitment to medical innovation.

This month's new research initiatives are concentrated in key metropolitan areas, making participation accessible for many residents. The cities seeing new trials open include:

• New Orleans (3 new trials)
• Baton Rouge (2 new trials)
• Kenner (1 new trial)
• Lafayette (1 new trial)

This distribution highlights the continued importance of New Orleans and Baton Rouge as major research hubs, while also extending opportunities to other communities like Kenner and Lafayette.

The new studies are exploring a diverse range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Asthma
• High-grade partial or full thickness rotator cuff tears
• HIV
• HIV prevention
• Iron absorption
• Meningioma
• Obesity
• Solid tumors
• STIs
• STIs prevention

The types of interventions being studied are varied, with 3 trials categorized as "OTHER," 2 as "DRUG" trials, 1 as a "COMBINATION_PRODUCT" trial, and 1 as a "DEVICE" trial. This diversity reflects the broad scope of research being conducted in Louisiana.

Academic institutions and industry sponsors are both driving significant research efforts. Pennington Biomedical Research Center, Ochsner Health System, and Westat are among the academic and "OTHER" sponsors, accounting for 4 of the new trials. Industry sponsors, including AstraZeneca, Incyte Corporation, and Jazz Pharmaceuticals, are leading 3 of the new studies this month, bringing their expertise to critical areas like oncology and respiratory health.

As Louisiana moves through spring, the ongoing enrollment in these significant Phase 2 and 3 trials, alongside the urgent need for participants in closing studies, underscores the dynamic nature of clinical research. Residents are encouraged to explore these opportunities and contribute to the future of healthcare.